# Surgical indication and management of obstructive colonic metastasis from primary lung adenocarcinoma: report of a case and review of the literature

**Authors:** Mai Watanabe, Shingo Tsujinaka, Tomoya Miura, Yoshihiro Sato, Yoh Kitamura, Kentaro Sawada, Atsushi Mitamura, Hiroto Sakurai, Noriko Kondo, Kazuhiro Takami, Kuniharu Yamamoto, Toru Nakano, Yu Katayose, Naruo Yoshimura, Chikashi Shibata

PMC · DOI: 10.1186/s40792-024-02016-3 · 2024-09-18

## TL;DR

A patient with lung cancer and colonic metastasis achieved intermediate-term survival through a combination of surgery, chemotherapy, and immunotherapy.

## Contribution

This case report highlights the potential benefit of surgical resection in managing obstructive colonic metastasis from lung cancer.

## Key findings

- The patient survived 13 months after surgery without disease progression.
- Surgical resection of the colonic metastasis was followed by a multimodal treatment approach.
- The histological type of the colonic tumor was consistent with metastatic lung adenocarcinoma.

## Abstract

Colonic metastasis from lung cancer is very rare and is typically associated with poor prognosis. Herein, we report the case of a patient who achieved intermediate-term survival using a multimodal treatment approach, including chemotherapy, immunotherapy, radiotherapy, and surgical resection for obstructive colonic metastasis from primary lung adenocarcinoma.

A woman in her 50s presented with anemia and a positive fecal occult blood test. Computed tomography revealed a tumor in the right upper lobe of the lung with mediastinal lymphadenopathy and wall thickening in the transverse colon. Colonoscopy revealed a stricture involving 50% of the colonic lumen. Biopsy revealed a poorly differentiated adenocarcinoma positive for CK-7 and TTF-1, very focally positive for napsin A, and negative for CK-20 and CDX-2. Furthermore, positron emission tomography/CT (PET/CT) showed a high maximum standardized uptake value (SUVmax) of 8.2 in the iliac bone. Based on these findings, the patient was diagnosed with primary lung adenocarcinoma with simultaneous metastasis to the transverse colon and iliac bone (cT4N3M1c, cStage IVB).

After receiving first-line chemotherapy with atezolizumab, pemetrexed, and carboplatin, the tumors shrank after 4 courses. Subsequently, the patient received maintenance therapy with atezolizumab and pemetrexed. However, the tumor enlarged after 10 courses. Second-line chemotherapy with docetaxel and ramucirumab (3 courses) failed to achieve tumor reduction. Colonoscopy revealed an impassable colonic tumor. Nineteen months after diagnosis, surgery was planned for imminent intestinal obstruction.

We determined that the colonic tumor was resectable, because laparoscopic exploration revealed no other metastases. The tumor was resected by partial colectomy with ileocolonic anastomosis. The postoperative course was uneventful. Pathological examination revealed a resection margin that was negative for malignancy, and the histological type was consistent with metastatic lung adenocarcinoma.

The patient then received nab-paclitaxel therapy; however, she developed symptoms of superior vena cava syndrome after 3 courses. The patient received palliative irradiation (30 Gy/10 fr) followed by nivolumab. She soon developed a solitary brain metastasis, and stereotactic irradiation was planned. After 3 courses of nivolumab, the metastasis was reduced significantly, and stereotactic brain irradiation was canceled. The lung tumor and mediastinal lymphadenopathy gradually shrank, and the patient survived for 13 months after surgery without disease progression.

In this case, surgical resection of colonic metastasis from primary lung adenocarcinoma may have contributed to the short-term prognosis as a bridge-to-next available multimodal treatment.

## Linked entities

- **Proteins:** KRT7 (keratin 7), TTF1 (transcription termination factor 1), Napsa (napsin A aspartic peptidase), KRT20 (keratin 20), CDX2 (caudal type homeobox 2)
- **Chemicals:** pemetrexed (PubChem CID 135410875), carboplatin (PubChem CID 426756), docetaxel (PubChem CID 148124), nab-paclitaxel (PubChem CID 36314)
- **Diseases:** lung adenocarcinoma (MONDO:0005061), superior vena cava syndrome (MONDO:0043287)

## Full-text entities

- **Genes:** KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, NAPSA (napsin A aspartic peptidase) [NCBI Gene 9476] {aka KAP, Kdap, NAP1, NAPA, NR1H2-AS1, SNAPA}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, TTF1 (transcription termination factor 1) [NCBI Gene 7270] {aka TTF-1, TTF-I}, CDX2 (caudal type homeobox 2) [NCBI Gene 1045] {aka CDX-3, CDX2/AS, CDX3}
- **Diseases:** malignancy (MESH:D009369), stricture (MESH:D003251), anemia (MESH:D000740), lung cancer (MESH:D008175), lung adenocarcinoma (MESH:D000077192), colonic tumor (MESH:D003110), intestinal obstruction (MESH:D007415), superior vena cava syndrome (MESH:D013479), PRESENTATION (MESH:D001946), mediastinal lymphadenopathy (MESH:D008477), colon and iliac bone (MESH:D003108), adenocarcinoma (MESH:D000230), Colonic metastasis (MESH:D009362)
- **Chemicals:** carboplatin (MESH:D016190), atezolizumab (MESH:C000594389), pemetrexed (MESH:D000068437), nivolumab (MESH:D000077594), ramucirumab (MESH:C543333), docetaxel (MESH:D000077143)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11410748/full.md

---
Source: https://tomesphere.com/paper/PMC11410748